The companies reported that IBA Molecular would acquire the Mallinckrodt business in a deal first announced in August 2016. The new entity will encompass 21 manufacturing centers (including three SPECT sites, one molybdenum manufacturing facility, and 17 PET sites), as well as commercial operations across 60 countries.
It will also employ more than 1,500 people globally, supplying more than 6,000 public and private hospitals around the world with its systems.
Nuclear imaging will be the core of the enlarged business, and a new name and brand is currently being developed, due to be rolled out in the coming months. In the interim, the firms will continue to operate as IBA Molecular and Mallinckrodt Nuclear Imaging. Renaud Dehareng, the current CEO of IBA Molecular, is also the new CEO of the enlarged group.
Copyright © 2017 AuntMinnieEurope.com